Abilify

Abilify Maintena (aripiprazole) is an intramuscular (IM), once-monthly injectable formulation for maintenance treatment of schizophrenia in adult patients stabilized with oral aripiprazole.

Abilify Maintena (aripiprazole)is an intramuscular (IM), once-monthly injectable formulation for maintenance treatment of schizophrenia in adult patients stabilized with oral aripiprazole.

Abilify is produced by Danish CNS drug specialist Lundbeck (LUN: CO) and Japanese drugmaker Otsuka Pharmaceutical’s (TYO: 4768) European subsidiary.

The 2014 launch of Abilify in Europe follows approval by the European Commission in November 21, 2013. In clinical trials, Abilify provided protection from relapse over the longterm with over 90% of patients remaining relapse-free at the end of the study period. It offers long-term control of positive and negative symptoms and can help preserve patients' personal and social functioning while offering a favourable tolerability profile similar to oral aripiprazole6.


Latest Articles

Back to top